{"id":"https://openalex.org/W4367302811","doi":"https://doi.org/10.1212/wnl.0000000000203853","title":"Patterns of Disease Modifying Therapy Utilization in Women with Multiple Sclerosis Before, During, and After Pregnancy (P9-3.016)","display_name":"Patterns of Disease Modifying Therapy Utilization in Women with Multiple Sclerosis Before, During, and After Pregnancy (P9-3.016)","publication_year":2023,"publication_date":"2023-04-25","ids":{"openalex":"https://openalex.org/W4367302811","doi":"https://doi.org/10.1212/wnl.0000000000203853"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.0000000000203853","doi":"https://doi.org/10.1212/wnl.0000000000203853","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000203853","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071392153","display_name":"Anna A. Shah","orcid":"https://orcid.org/0000-0002-0580-0248","observed_orcids":["https://orcid.org/0000-0002-0580-0248"]},"institutions":[{"id":"https://openalex.org/I4210155879","display_name":"Rocky Mountain MS Center","ror":"https://ror.org/059kzn841","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210155879"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anna Shah","raw_affiliation_strings":["University of Colorado, Rocky Mountain MS Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado, Rocky Mountain MS Center","institution_ids":["https://openalex.org/I4210155879"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051842646","display_name":"Riley M. Bove","orcid":"https://orcid.org/0000-0002-2034-8800","observed_orcids":["https://orcid.org/0000-0002-2034-8800"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Riley Bove","raw_affiliation_strings":["Department of Neurology, UCSF Weill Institute for Neurosciences, University of California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, UCSF Weill Institute for Neurosciences, University of California","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081807013","display_name":"Angela Applebee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Angela Applebee","raw_affiliation_strings":["St. Peter\u2019s Health Partners"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St. Peter\u2019s Health Partners","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114179865","display_name":"Katrina Bawden","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210109961","display_name":"Rocky Mountain Multiple Sclerosis Clinic","ror":"https://ror.org/015dsp568","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210109961"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katrina Bawden","raw_affiliation_strings":["Rocky Mountain MS Clinic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rocky Mountain MS Clinic","institution_ids":["https://openalex.org/I4210109961"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053985159","display_name":"Celeste Fine","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Celeste Fine","raw_affiliation_strings":["Gilbert Neurology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilbert Neurology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001549810","display_name":"Robin L. Avila","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robin Avila","raw_affiliation_strings":["Biogen Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Inc","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054973348","display_name":"Nicholas Belviso","orcid":"https://orcid.org/0000-0002-1740-3418","observed_orcids":["https://orcid.org/0000-0002-1740-3418"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicholas Belviso","raw_affiliation_strings":["Biogen Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Inc","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111781049","display_name":"Filipe Branco","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Filipe Branco","raw_affiliation_strings":["Biogen Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Inc","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068265220","display_name":"Kinyee Fong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kinyee Fong","raw_affiliation_strings":["Biogen Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Inc","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079435549","display_name":"James B. Lewin","orcid":"https://orcid.org/0000-0002-2352-9113","observed_orcids":["https://orcid.org/0000-0002-2352-9113"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Lewin","raw_affiliation_strings":["Biogen Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Inc","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029376347","display_name":"Jieruo Liu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jieruo Liu","raw_affiliation_strings":["Biogen Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Inc","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110843766","display_name":"Sarah M England","orcid":"https://orcid.org/0009-0008-0232-278X","observed_orcids":["https://orcid.org/0009-0008-0232-278X"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah England","raw_affiliation_strings":["Biogen Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Inc","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5057692943","display_name":"Megan Vignos","orcid":"https://orcid.org/0000-0002-7755-2781","observed_orcids":["https://orcid.org/0000-0002-7755-2781"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Megan Vignos","raw_affiliation_strings":["Biogen Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Inc","institution_ids":["https://openalex.org/I1297540436"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"100","issue":"17_supplement_2","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9394999742507935,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9394999742507935,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11964","display_name":"Pregnancy and Medication Impact","score":0.059700001031160355,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12230","display_name":"Cardiovascular Issues in Pregnancy","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":0.9959999918937683},{"id":"https://openalex.org/keywords/disease-modifying-therapy","display_name":"disease-modifying therapy","score":0.9440000057220459},{"id":"https://openalex.org/keywords/pregnancy","display_name":"pregnancy","score":0.9449999928474426},{"id":"https://openalex.org/keywords/postpartum-period","display_name":"postpartum period","score":0.9010000228881836},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.7409999966621399},{"id":"https://openalex.org/keywords/treatment-patterns","display_name":"treatment patterns","score":0.4059999883174896},{"id":"https://openalex.org/keywords/natalizumab","display_name":"natalizumab","score":0.8740000128746033},{"id":"https://openalex.org/keywords/glatiramer-acetate","display_name":"glatiramer acetate","score":0.9860000014305115},{"id":"https://openalex.org/keywords/dimethyl-fumarate","display_name":"dimethyl fumarate","score":0.8429999947547913},{"id":"https://openalex.org/keywords/interferon","display_name":"interferon","score":0.6779999732971191},{"id":"https://openalex.org/keywords/fingolimod","display_name":"fingolimod","score":0.968999981880188},{"id":"https://openalex.org/keywords/women-s-health","display_name":"women's health","score":0.39800000190734863},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.3630000054836273}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8756512403488159},{"id":"https://openalex.org/C2778577042","wikidata":"https://www.wikidata.org/wiki/Q418274","display_name":"Glatiramer acetate","level":3,"score":0.8706701993942261},{"id":"https://openalex.org/C2781004633","wikidata":"https://www.wikidata.org/wiki/Q386119","display_name":"Natalizumab","level":3,"score":0.8649558424949646},{"id":"https://openalex.org/C2779234561","wikidata":"https://www.wikidata.org/wiki/Q11995","display_name":"Pregnancy","level":2,"score":0.862430214881897},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.7078251838684082},{"id":"https://openalex.org/C3018745865","wikidata":"https://www.wikidata.org/wiki/Q749115","display_name":"Postpartum period","level":3,"score":0.5229616761207581},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.5114716291427612},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.43966159224510193},{"id":"https://openalex.org/C2776534028","wikidata":"https://www.wikidata.org/wiki/Q1141363","display_name":"Medicaid","level":3,"score":0.43775707483291626},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.43337318301200867},{"id":"https://openalex.org/C131872663","wikidata":"https://www.wikidata.org/wiki/Q5284418","display_name":"Obstetrics","level":1,"score":0.38955697417259216},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2975367307662964},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.18162116408348083},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.08947616815567017},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.0000000000203853","doi":"https://doi.org/10.1212/wnl.0000000000203853","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000203853","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4399849978","https://openalex.org/W7167848901","https://openalex.org/W2920748704","https://openalex.org/W4391293995","https://openalex.org/W4367302742","https://openalex.org/W4210478146","https://openalex.org/W4409227639","https://openalex.org/W2954604596","https://openalex.org/W2791359232","https://openalex.org/W2906840863"],"abstract_inverted_index":{"Objective:":[0],"To":[1,60],"evaluate":[2],"disease-modifying":[3],"therapy":[4],"(DMT)":[5],"utilization":[6,173,276],"for":[7,25,55,98,317,328,344,355,369,391,396,409,420,433,444,457,468,482,493,507,518,531,542,556,567,580,591,638,643,656,661,674,679,692,697,710,716,729,735,750,756,769,775,788,794,809,815,829,835,848,854,862,881,894,918,931,950,970,1000],"the":[8,34,41,88,151,190,193,313,340,365,387,405,429,453,478,503,527,552,576,634,652,670,688,706,725,746,765,784,805,825,844,996],"treatment":[9,73,224],"of":[10,36,124,139,148,305,315,332,342,367,389,407,431,455,480,505,529,554,578,595,606,618,636,654,672,690,708,727,748,767,786,807,827,846,867,886,899,923,936,955,975,998],"multiple":[11],"sclerosis":[12],"(MS)":[13],"before,":[14,75],"during":[15,40,69,76,144,279],"and":[16,45,71,77,92,108,133,161,168,180,207,231,239],"after":[17,78],"pregnancy.":[18],"Background:":[19],"Pregnancy":[20,44],"is":[21,31],"a":[22,49,320,347,372,394,412,436,460,485,510,534,559,583,641,659,677,695,713,732,753,772,791,812,832,851,1003],"common":[23],"consideration":[24],"women":[26],"with":[27,58,104,213,229,247,375,1005],"MS;":[28],"MS":[29,106,378],"onset":[30],"typically":[32],"between":[33],"ages":[35],"20\u201345":[37],"years,":[38,103],"i.e.,":[39],"child-bearing":[42],"years.":[43],"postpartum":[46,284],"care":[47],"are":[48,64],"significant":[50],"factor":[51],"influencing":[52],"DMT":[53,140,172,215,275],"selection":[54],"many":[56],"patients":[57,100,126,149,187,211,218],"MS.":[59],"date,":[61],"few":[62],"DMTs":[63,197],"considered":[65],"safe":[66],"to":[67,155,158,175,222,236,242,251,257,264,271],"continue":[68,223],"pregnancy":[70,79,156],"real-world":[72],"patterns":[74],"remain":[80],"uncharacterized.":[81],"Design/Methods:":[82],"In":[83],"this":[84],"retrospective,":[85],"observational":[86],"study,":[87],"US":[89],"MarketScan":[90],"Commercial":[91],"Medicaid":[93],"claims":[94,114],"database":[95],"was":[96,127],"assessed":[97],"female":[99],"aged":[101],"18\u201355":[102],"an":[105,865,884,897,907,921,934,953,973],"diagnosis":[107],"\u22651":[109],"delivery-related":[110],"inpatient":[111],"or":[112,267,323,350,415,439,463,488,513,537,562,586,906],"outpatient":[113],"from":[115,146,602,613,625,910],"01":[116],"January":[117],"2016\u201330":[118],"April":[119],"2021.":[120],"Results:":[121],"A":[122],"cohort":[123],"944":[125],"identified;":[128],"688":[129],"(73%)":[130],"were":[131,198,219],"commercially-insured":[132],"256":[134],"(27%)":[135],"received":[136,309,336,361,383,401,425,449,474,499,523,548,572,599,610,622,630,648,666,684,702,721,742,761,780,801,821,840,859,878,891,904,915,928,947,967,992],"Medicaid.":[137],"Prevalence":[138],"use":[141],"declined":[142,277],"sharply":[143,278],"pregnancy,":[145],"36.3%":[147],"in":[150,163,189,216,312,339,364,386,404,428,452,477,502,526,551,575,633,651,669,687,705,724,745,764,783,804,824,843,873,942,962,981,987,995],"6":[152],"months":[153,179,294],"prior":[154],"(pre-pregnancy)":[157],"17.9%,":[159],"5.3%":[160],"5.8%":[162],"trimesters":[164],"(T)":[165],"1,":[166],"2":[167],"3,":[169],"respectively.":[170],"Postpartum":[171],"increased":[174,283],"20.9%":[176],"at":[177,182],"0\u20133":[178],"24.4%":[181],"4\u20136":[183],"months.":[184],"Of":[185,210],"all":[186],"(n=944)":[188],"pre-pregnancy":[191,288],"period,":[192],"most":[194],"frequently":[195],"used":[196],"glatiramer":[199,232],"acetate":[200,233],"(15.0%),":[201],"dimethyl":[202,260],"fumarate":[203,261],"(6.4%),":[204],"interferon":[205,248],"(5.4%)":[206],"natalizumab":[208,230],"(5.2%).":[209],"treated":[212,228],"any":[214],"T1,":[217],"more":[220],"likely":[221],"into":[225],"T3":[226],"if":[227],"(60.9%":[234],"[T1]":[235,241,250,256,263,270],"10.9%":[237],"[T3]":[238],"54.8%":[240],"20.7%":[243],"[T3],":[244],"respectively)":[245],"compared":[246],"(36.7%":[249],"8.2%":[252],"[T3]),":[253,259,266],"fingolimod":[254],"(35.1%":[255],"8.1%":[258],"(28.1%":[262],"7.0%":[265],"ocrelizumab":[268],"(6.7%":[269],"0%":[272],"[T3]).":[273],"Conclusions:":[274],"pregnancy;":[280],"it":[281],"gradually":[282],"but":[285],"remained":[286],"below":[287],"use.":[289],"Infusibles":[290],"administered":[291],"every":[292],"6\u201312":[293],"(e.g.,":[295],"anti-CD20":[296],"medications)":[297],"may":[298],"have":[299],"been":[300],"underestimated.":[301],"Disclosure:":[302],"The":[303,330,593,604,616],"institution":[304,331,594,605,617],"Dr.":[306,333,358,380,398,422,446,471,496,520,545,569,596,607,619,627,645,663,681,699,718,875,912,925,938,964,977,983,989],"Shah":[307,334,359],"has":[308,335,360,382,400,424,448,473,498,522,547,571,598,609,621,629,647,665,683,701,720,741,760,779,800,820,839,858,871,877,890,903,914,927,940,946,960,966,979,985,991],"personal":[310,337,362,384,402,426,450,475,500,524,549,573,631,649,667,685,703,722,743,762,781,802,822,841,860,879,892,916,929,948,968,993],"compensation":[311,338,363,385,403,427,451,476,501,525,550,574,632,650,668,686,704,723,744,763,782,803,823,842,861,880,893,917,930,949,969,994],"range":[314,341,366,388,406,430,454,479,504,528,553,577,635,653,671,689,707,726,747,766,785,806,826,845,997],"$500-$4,999":[316,343,408,555,579,709,728,768],"serving":[318,345,370,392,410,434,458,483,508,532,557,581,639,657,675,693,711,730,751,770,789,810,830,849,863,882,895,919,932,951,971,1001],"on":[319,346,411,435,459,484,509,533,558,582,712,731,752,771,790,811,831,850],"Scientific":[321,348,413,437,461,486,511,535,560,584],"Advisory":[322,349,414,438,462,487,512,536,561,585],"Data":[324,351,416,440,464,489,514,538,563,587],"Safety":[325,352,417,441,465,490,515,539,564,588],"Monitoring":[326,353,418,442,466,491,516,540,565,589],"board":[327,354,419,443,467,492,517,541,566,590],"Genentech.":[329,615,662],"TG":[356,543,816],"Therapeutics.":[357,544],"$5,000-$9,999":[368,390,432,456,673,691,787,808,828],"as":[371,393,640,658,676,694,864,883,896,920,933,952,972,1002],"Educational":[373],"Speaker":[374],"Rocky":[376],"Mountain":[377],"Center.":[379],"Bove":[381,399,423,447,472,497,521,546,570,597,608,620],"Consultant":[395,642,660,678,696],"Biogen.":[397,445,603,644,757,836,868,874,887,900,911,924,937,943,963,976,982,988,1006],"Horizon.":[421,717],"EMD":[469],"Serono.":[470,698],"$10,000-$49,999":[481,506,530,637,655,749,847],"Genzyme":[494],"Sanofi.":[495],"Novartis.":[519,626],"Jansen.":[568],"Alexion.":[592],"research":[600,611,623],"support":[601,612,624],"Roche":[614],"Applebee":[628,646,664,682,700,719],"Genzyme.":[680],"Speakers":[714,733,754,773,792,813,833,852],"Bureau":[715,734,755,774,793,814,834,853],"Bristol":[736],"Myers":[737],"Squibb.":[738],"Ms.":[739,758,777,798,818,837,944,958],"Bawden":[740,759,778,799],"Biohaven.":[776],"Banner":[795],"Life":[796],"Sciences.":[797],"therapeutics.":[817],"Fine":[819,838],"Abbvie.":[855],"Mrs.":[856,869],"Avila":[857,870],"employee":[866,885,898,922,935,954,974],"stock":[872,905,941,961,980,986],"Belviso":[876],"Filipe":[888,901],"Branco":[889,902],"ownership":[908],"interest":[909],"Fong":[913],"Lewin":[926,939],"LIU":[945,959],"Biogen":[956],".":[957],"England":[965,978],"Vignos":[984,990],"$100,000-$499,999":[999],"Employee":[1004]},"counts_by_year":[],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2023-04-29T00:00:00"}